NantHealth (NASDAQ:NH) has been given a $5.00 price objective by analysts at Jefferies Group in a note issued to investors on Wednesday. The brokerage currently has a “buy” rating on the stock. Jefferies Group’s price objective points to a potential upside of 65.02% from the stock’s current price.
A number of other equities research analysts also recently issued reports on the company. BidaskClub downgraded NantHealth from a “sell” rating to a “strong sell” rating in a research report on Wednesday, December 6th. Zacks Investment Research downgraded NantHealth from a “buy” rating to a “hold” rating in a research report on Wednesday, December 20th. Finally, Cowen reiterated a “buy” rating and issued a $4.50 price objective on shares of NantHealth in a research report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $7.46.
Shares of NH stock opened at $3.03 on Wednesday. The stock has a market capitalization of $338.77, a price-to-earnings ratio of -2.03 and a beta of 0.64. NantHealth has a 12-month low of $2.60 and a 12-month high of $5.72. The company has a current ratio of 2.28, a quick ratio of 2.36 and a debt-to-equity ratio of 1.01.
In related news, COO Ronald Allen Louks sold 7,095 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $3.56, for a total value of $25,258.20. Following the sale, the chief operating officer now directly owns 89,690 shares of the company’s stock, valued at $319,296.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold 19,745 shares of company stock worth $66,549 over the last three months. 58.00% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently modified their holdings of NH. Millennium Management LLC purchased a new position in shares of NantHealth during the fourth quarter valued at approximately $344,000. Deutsche Bank AG lifted its holdings in shares of NantHealth by 117.4% during the fourth quarter. Deutsche Bank AG now owns 45,610 shares of the company’s stock valued at $137,000 after purchasing an additional 24,635 shares during the last quarter. Advisor Group Inc. purchased a new position in shares of NantHealth during the fourth quarter valued at approximately $450,000. Citadel Advisors LLC purchased a new position in shares of NantHealth during the fourth quarter valued at approximately $103,000. Finally, SG Americas Securities LLC lifted its holdings in shares of NantHealth by 157.6% during the fourth quarter. SG Americas Securities LLC now owns 72,521 shares of the company’s stock valued at $221,000 after purchasing an additional 44,372 shares during the last quarter. Institutional investors and hedge funds own 6.27% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “NantHealth (NH) PT Set at $5.00 by Jefferies Group” was originally reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.thelincolnianonline.com/2018/03/21/nanthealth-nh-pt-set-at-5-00-by-jefferies-group.html.
NantHealth Company Profile
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.